摘要 |
An object of the present invention is to provide a pharmaceutical composition for the treatment of secondary hyperparathyroidism, which can reduce the risk of inducing cardiovascular complications associated with calcification, as well as a therapeutic or prophylactic agent for cardiovascular complications (e.g., arteriosclerosis, ischemic heart disease) associated with calcification resulting from the treatment of secondary hyperparathyroidism in a hemodialysis patient. The present invention provides a pharmaceutical composition for the treatment of secondary hyperparathyroidism, which comprises, as an active ingredient, a vitamin D derivative not having an inducing action on cardiovascular complications associated with calcification, as well as a therapeutic agent for cardiovascular complications associated with calcification resulting from the treatment of secondary hyperparathyroidism in a hemodialysis patient, which comprises 1alpha,3beta-dihydroxy-20S-(3-hydroxy-3-methylbutyloxy)-9,10-seco-5,7,10(19)-pregnatriene as an active ingredient.
|